NCT03715959Completed
Nipple Aspirate Fluid in Detecting Breast Cancer
Phi29 Motor Nanopore for Single Molecule Sensing: Breast Nipple Aspirate Fluid
Source: ClinicalTrials.gov · Last updated 25 Feb 2025
Brief summary (registry, in English)
This trial studies nipple aspirate fluid in detecting breast cancer. Nipple aspirate fluid may better detect breast cancer earlier than current methods used for screening such as mammograms and breast examinations.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 2 (actual)
- First submitted
- 19 Oct 2018
- Start date
- 10 Dec 2020
- Primary completion date
- 1 Jan 2024
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- NCT number
- NCT03715959
What you commit to
- Study type: Interventional
- Participants enrolled: 2
- From 10 Dec 2020 to the primary completion date, 1 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects who currently are diagnosed with cancers other than breast cancer.
Age
- Subjects who are currently pregnant, lactating, or within a year of pregnancy/lactation. Pregnancy testing will not be required of any patients over 60 years of age, or any patient who has undergone bilateral oophorectomy.
- Male gender of any age.
Other
- Subjects who cannot give an informed consent.
Who the study is looking for
- BREAST CANCER: Must be \> 1 year from pregnancy, lactation.
- BREAST CANCER: Must be currently diagnosed with known breast cancer in breast.
- BREAST CANCER: Must not be currently diagnosed with cancers other than breast cancer.
- BREAST CANCER: Must not have been gone through surgery, radiotherapy or chemotherapy within 30 days of enrollment.
- HEALTHY SUBJECTS: No history of breast cancer and must not be currently diagnosed with any other cancer.
- HEALTHY SUBJECTS: Must be \> 1 year from pregnancy, lactation.
- HEALTHY SUBJECTS: Must be willing to have a clinical breast exam and/or mammogram performed or reviewed by an Ohio State University (OSU) radiologist at the James Cancer Hospital within the past 90 days prior to their NAF procedure. The clinical breast exam result and/or mammograms must be read as not suspicious for breast cancer.
- HEALTHY SUBJECTS: Must be willing to keep the clinic informed of their breast health status for 1 year.
Age in the registry: 40 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ohio State University Comprehensive Cancer Center Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.